Cargando…
Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab
Psoriasis vulgaris is a chronic immune-mediated inflammatory disease of the skin. Biologic therapy has been available for more than 10 years and has become one of the standard treatments for patients with moderate to severe psoriasis. Initially, only biologics against tumour necrosis factor alpha (T...
Autores principales: | Gkalpakiotis, Spyridon, Fridman, Marketa, Tivadar, Simona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850508/ https://www.ncbi.nlm.nih.gov/pubmed/35067854 http://dx.doi.org/10.1007/s13555-021-00672-z |
Ejemplares similares
-
A Patient with Adalimumab-Induced Refractory Paradoxical Palmoplantar Pustulosis Was Successfully Treated by Ixekizumab: A Case Report
por: Shao, Xin-Yi, et al.
Publicado: (2023) -
Successful Treatment of a Patient with Pyoderma Gangrenosum, Plaque Psoriasis and Palmoplantar Pustulosis with Adalimumab
por: Chu, Yuqi, et al.
Publicado: (2022) -
SAPHO Syndrome with Palmoplantar Pustulosis as the First Manifestation Successfully Treated with Adalimumab
por: Yang, Qingyun, et al.
Publicado: (2022) -
Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report
por: Li, Qing-Yang, et al.
Publicado: (2020) -
Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)